Calculate the Revised Geneva Score for pulmonary embolism probability. Objective, standardized PE risk assessment using 8 clinical criteria without subjective judgment.
The Revised Geneva Score is a validated clinical prediction rule for estimating the pre-test probability of pulmonary embolism (PE). Unlike the Wells score, which includes the subjective criterion "PE is the most likely diagnosis," the Revised Geneva Score uses exclusively objective criteria, making it fully standardized and reproducible across different clinicians.
Developed by Le Gal et al. in 2006, the score uses 8 clinical variables: age, prior VTE, recent surgery or fracture, active malignancy, unilateral leg pain, hemoptysis, heart rate, and leg edema with deep vein tenderness. The total score stratifies patients into low (0-3), intermediate (4-10), and high (≥11) probability categories, each with distinct PE prevalence and recommended diagnostic pathways.
The Revised Geneva Score has been validated in multiple large multicenter studies and is endorsed by the European Society of Cardiology (ESC) alongside the Wells score for PE probability assessment. Its objective nature makes it particularly valuable for research, quality metrics, and settings where standardization is prioritized.
The key advantage of the Revised Geneva Score over the Wells score is its complete objectivity — no criterion requires subjective clinical judgment. This eliminates inter-observer variability and makes it ideal for clinical decision support systems, triage protocols, and research settings where reproducibility is essential.
When used within a validated diagnostic algorithm (risk stratification → D-dimer → imaging), the Revised Geneva Score safely excludes PE in the majority of low and intermediate probability patients without CT imaging.
Revised Geneva Score: Age 65-75: +1 | Age >75: +2 Previous DVT/PE: +3 Surgery or fracture (≤1 month): +2 Active malignancy: +2 Unilateral lower limb pain: +3 Hemoptysis: +2 HR 75-94: +3 | HR ≥95: +5 Pain on DVP palpation + unilateral edema: +4 Range: 0-22 0-3: Low (8%) | 4-10: Intermediate (29%) | ≥11: High (74%)
Result: Revised Geneva Score 10 — Intermediate Probability
Age >75 (2 pts) + prior DVT/PE (3 pts) + HR ≥95 (5 pts) = 10 points. Intermediate probability with approximately 29% PE prevalence. D-dimer testing is indicated. If D-dimer is elevated, CT pulmonary angiography should be performed. If D-dimer is negative, PE can be safely excluded.
Step 1: Calculate Revised Geneva Score. Step 2: Low probability (0-3): apply PERC if available, or D-dimer. Step 3: Intermediate probability (4-10): D-dimer; if positive → CTPA. Step 4: High probability (≥11): CTPA directly (D-dimer unreliable at high pre-test probability). Step 5: If CTPA is contraindicated: V/Q scan or bilateral compression ultrasound.
D-dimer effectively rules out PE in low and intermediate probability patients with a negative predictive value >99%. However, D-dimer is often falsely positive in elderly, post-surgical, cancer, pregnant, and hospitalized patients. Age-adjusted thresholds and YEARS algorithm improve specificity without sacrificing sensitivity.
Scoring tools assess probability of PE existence, not severity. Once PE is diagnosed: Massive PE (hemodynamic instability): systemic thrombolysis, surgical thrombectomy, or catheter-directed therapy. Submassive PE (RV dysfunction without hypotension): anticoagulation ± escalation. Low-risk PE: anticoagulation, possibly outpatient management using PESI score.
Both scores have similar diagnostic accuracy for PE. The Wells score is more widely used in North America, while the Revised Geneva Score is favored in Europe. Choose the Geneva score when objectivity is important (protocols, EMR decision support) and the Wells score when clinical gestalt adds value. Either is acceptable per ESC and ACEP guidelines.
A simplified Revised Geneva Score assigns 1 point to each criterion (instead of variable weights). The simplified version is easier to calculate and has comparable accuracy: low (0-1), intermediate (2-4), high (≥5). It is commonly used in clinical practice and is validated in many studies.
Age is a continuous risk factor for PE. The Geneva score uses cutoffs: ages 65-75 add 1 point, >75 adds 2 points. This reflects the exponential increase in PE incidence with age (from <1 per 1000 at age 30 to >5 per 1000 at age 80). Age-adjusted D-dimer thresholds (age × 10 μg/L) further improve the algorithm in elderly patients.
The Revised Geneva Score has not been specifically validated in pregnancy. Pregnant patients have altered physiology (higher heart rate, changed hemostasis) and different PE risk profiles. Specific pregnancy PE algorithms using V/Q scan and compression ultrasonography are recommended.
Active malignancy means cancer diagnosed within the past 6-12 months, active treatment (chemotherapy, radiation), or metastatic/advanced disease. Cancer in remission for several years and adequately treated non-melanoma skin cancer generally do not count. Cancer-associated VTE has unique pathophysiology and treatment considerations.
The score counts heart rate regardless of etiology. A patient tachycardic from fever, pain, or anxiety will score higher even if the tachycardia is not from PE. This is a limitation — but tachycardia from any cause in a patient where PE is considered warrants investigation, as PE often coexists with other conditions.